Belumosudil: all 38 studies that test it

Page 1 of 1. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host DiseaseNot yet recruitingNCT07771439Phase 3
• Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male ParticipantsNot yet recruitingNCT07726914Phase 1
• Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD)Not yet recruitingNCT07643025Phase 2
• IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHDNot yet recruitingNCT07484113Phase 1
• A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)Not yet recruitingNCT07135973Phase 4
• Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHDRecruitingNCT07127926Phase 1
• A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)RecruitingNCT07116031Phase 2
• A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell TransplantRecruitingNCT07006506Phase 2
• Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney TransplantationEnrolling by invitationNCT06751602Phase 2
• NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid TumorsRecruitingNCT06509490Not applicable
• Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant RecipientsRecruitingNCT06476132Phase 2
• Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT06105554Phase 1/2
• A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft DysfunctionRecruitingNCT06082037Phase 3
• Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host DiseaseRecruitingNCT05996627Phase 2
• NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid TumorsRecruitingNCT05382377Early Phase 1
• Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213CompletedNCT05305989Phase 2Results posted
• Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)CompletedNCT04930562Phase 2Results posted
• Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic SclerosisTerminatedNCT04680975Phase 2Results posted
• KD025 in Subjects With Diffuse Cutaneous Systemic SclerosisTerminatedNCT03919799Phase 2Results posted
• Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025CompletedNCT03907540Phase 1Results posted
• Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic TherapyTerminatedNCT03640481Phase 2Results posted
• Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy VolunteersCompletedNCT03530995Phase 1Results posted
• A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque PsoriasisCompletedNCT02852967Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host DiseaseCompletedNCT02841995Phase 2Results posted
• A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary FibrosisCompletedNCT02688647Phase 2Results posted
• Bioavailability of Belumosudil (KD025) in Healthy Male SubjectsCompletedNCT02557139Phase 1Results posted
• Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line TherapyCompletedNCT02317627Phase 2Results posted
• A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis VulgarisCompletedNCT02106195Phase 2Results posted
• A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic TherapiesCompletedNCT06616415Phase 4
• A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.Active, not recruitingNCT06143891Phase 3
• Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-DiseaseSuspendedNCT06046248Phase 2
• A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male SubjectsCompletedNCT05918627Phase 1
• A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female SubjectsCompletedNCT05918614Phase 1
• A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female SubjectsCompletedNCT05918588Phase 1
• Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic TherapyWithdrawnNCT05567406Phase 2
• A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative BioavailabilityCompletedNCT04735822Early Phase 1
• NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ TumorsStatus unknownNCT04550663Phase 1
• KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic ImpairmentCompletedNCT04166942Phase 1

← Belumosudil overview